Bain Capital Public Equity Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Bain Capital Public Equity Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-42,026	Closed	-$4.28M	–	90
2017 Q3	$4.28M	Sell	42,026 -29,110	-41%	-$2.54M	0.27%	45
2017 Q2	$5.44M	Buy	71,136 +16,536	+30%	+$1.39M	0.33%	41
2017 Q1	$4.71M	Buy	+54,600	New	+$3.93M	0.33%	51

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bain Capital Public Equity Management's LKFT Position: Q4 2017 in Review

Bain Capital Public Equity Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2017, closing a stake of 42,026 shares — an estimated $4.28M sold.

Bain Capital Public Equity Management first reported a position in LKFT in Q1 2017 and held it in 3 quarters. The position peaked at $5.44M in Q2 2017. 77 funds tracked by Wall St. Rank hold LKFT as of Q4 2017.

Bain Capital Public Equity Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2017 after selling out during the quarter.
Bain Capital Public Equity Management sold 42,026 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2017, an estimated $4.28M.
Bain Capital Public Equity Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2017 and held it in 3 quarters.
Bain Capital Public Equity Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $5.44M in Q2 2017.
77 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2017.

Based on Bain Capital Public Equity Management's 13F filing for Q4 2017, filed 14 Feb 2018.